Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study.

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Cross, Nikki (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date21/11/18 → 31/12/23